2020年4月9日 · Chimeric antigen receptor T-cell (CAR-T) therapy yields durable responses in patients with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL). Cytokine release syndrome (CRS) is a CAR-T therapy–related adverse event.

Cytokine release syndrome (CRS) is an acute systemic inflammatory syndrome characterized by fever and multiple organ dysfunction. CRS is most often associated with chimeric antigen receptor (CAR)-T cell therapy, but it also occurs in association with bispecific T cell engager therapy, other monoclonal antibody-based therapy, haploidentical ...

Assesses severity of CRS in patients on immunotherapy. Use in patients receiving immunotherapy for cancer. Other creator. Have feedback about this calculator? The Cytokine Release Syndrome Grading scales the degrees of severity of CRS.

CRS is “a supraphysiologic response following any immune therapy that results in the activation or engagement of endogenous or infused T cells and/or other immune effector cells. Symptoms can be progressive, must include fever at the onset and may include hypotension, capillary leak (hypoxia) and end organ dysfunction.”

2018年11月10日 · Here we report the consensus recommendations of that group and propose new definitions and grading for CRS and neurotoxicity that are objective, easy to apply, and ultimately more accurately categorize the severity of these toxicities.

Dexamethasone (10 mg q12-24 hrs) with tocilizumab initial tocilizumab. For patients refractory to dexamethasone can increase to 20 mg q 6-12 hrs. Tocilizumab 8 mg/kg (Consider alternative agents after 2 doses) *No more than 3 doses in a 24 hr period or 4 doses in total.

The Penn grading scale demonstrates how patients with grade 2 vs grade 3 vs grade 4 CRS differ, as supported by the differences in time to onset and duration of CRS, duration of high fevers, frequency of hypotension requiring vasopressors, and need for anti-cytokine therapy.

We summarized new developments in the grading, modeling, and therapeutic approaches for CRS and neurotoxicities in this review. CRS has characteristic clinical presentations, manifested typically with high fever, hypotension, hypoxia, and respiratory distress [41 – 44].

In this review, we will focus on describing the pathophysiology behind CRS, the proposed definitions of and grading systems for CRS, and innovative options for treating this potentially lethal systemic inflammatory condition.

Here we report the consensus recommendations of that group and propose new definitions and grading for CRS and neurotoxicity that are objective, easy to apply, and ultimately more accurately categorize the severity of these toxicities.